Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 469-475 , September 2009

Reproducibility patterns of plasma norepinephrine and muscle sympathetic nerve traffic in human obesity

Received 16 July 2008 ,Revised 22 August 2008 ,Accepted 13 September 2008.

References 

  1. Scherrer U, Randin D, Tappy L, Vollenweider P, Jequier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634–2640
  2. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–563
  3. Vaz M, Jennings G, Turner A, Cox H, Lambert G, Esler M. Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. Circulation. 1997;96:3423–3429
  4. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation. 1998;98:772–776
  5. Rumantir MS, Vaz M, Jennings GL, Collier G, Kaye DM, Seals DR, et al. Neural mechanisms in human obesity-related hypertension. J Hypertens. 1999;17:1125–1133
  6. Grassi G, Seravalle G, Dell'Oro R, Turri C, Bolla GB, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538–542
  7. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533–2536
  8. Grassi G, Facchini A, Quarti Trevano F, Dell'Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46:321–325
  9. Lambert E, Straznicky N, Schlaich M, Esler M, Dawood T, Hotchkin E, et al. Differing pattern of sympathoexcitation in normal-weight and obesity-related hypertension. Hypertension. 2007;50:862–868
  10. Grassi G, Quarti-Trevano F, Seravalle G, Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2007;17:473–481
  11. Young JB, MacDonald IA. Sympathoadrenal activity in human obesity: heterogeneity of findings since 1980. Int J Obes Relat Metab Disord. 1992;16:959–967
  12. Esler MD, Jennings G, Lambert G, Meredith I, Home M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate and functions. Physiol Rev. 1990;70:963–985
  13. Esler M, Lambert G, Brunner-La Rocca HP, Vaddadi G, Kaye D. Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice. Acta Physiol Scand. 2003;177:275–284
  14. Grassi G, Bolla G, Seravalle G, Turri C, Lanfranchi A, Mancia G. Comparison between reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci (Lond). 1997;92:285–289
  15. Seravalle G, Bolla GB, Turri C, Stella ML, Magnoni M, Grassi G, et al. Effects of multiple sampling on plasma norepinephrine reproducibility. J Hypertens. 1999;17:S45
  16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. European Society of Hypertension (ESH)/ European Society of Cardiology (ESC) 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens. 2007;25:1105–1187
  17. Groppelli A, Omboni S, Parati G, Mancia G. Evaluation of non-invasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intraarterial blood pressure. Hypertension. 1992;20:227–232
  18. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206–3211
  19. Hjemdahl P, Daleskong M, Kanan T. Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method. Life Sci. 1979;25:131–138
  20. Goldstein DS, Feuerstein GZ, Izzo JL, Kopin IJ, Keiser HR. Validity and reability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 1981;28:467–475
  21. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–310
  22. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17:719–734
  23. Grassi G. Renin-angiotensin-sympathetic crosstalks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens. 2001;19:1713–1716
  24. Landsberg L. Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001;19:523–528
  25. Grassi G. Leptin, sympathetic nervous system, and baroreflex function. Curr Hypertens Rep. 2004;6:236–240
  26. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension. 2004;43:169–175
  27. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, et al. Heart rate as marker of sympathetic activity. J Hypertens. 1998;16:1635–1639
  28. Waradekar NV, Sinoway LI, Zwillich CW, Leuenberger UA. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. Am J Respir Crit Care Med. 1996;153:1333–1338
  29. Imadojemu VA, Mawji Z, Kunselman A, Gray KS, Hogeman CS, Leuenberger UA. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest. 2007;131:1406–1413
  30. Wolf J, Lewicka J, Narkiewicz K. Obstructive sleep apnea: an update on mechanisms and cardiovascular consequences. Nutr Metab Cardiovasc Dis. 2007;17:233–240

PII: S0939-4753(08)00190-7

doi: 10.1016/j.numecd.2008.09.008

Nutrition, Metabolism & Cardiovascular Diseases
Volume 19, Issue 7 , Pages 469-475 , September 2009

Article Tools

* Image Usage & Resolution